Qube Research & Technologies (QRT)
TELO icon

Qube Research & Technologies (QRT)’s Telomir Pharmaceuticals TELO Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,015
Closed -$15.3K – 4159
2025
Q3 		$15.3K Sell
11,015
-15,494
-58% -$23.4K ﹤0.01% 3314
2025
Q2 		$33.1K Buy
+26,509
New +$61.3K ﹤0.01% 3205

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TELO Position: Q4 2025 in Review

Qube Research & Technologies (QRT) sold out of Telomir Pharmaceuticals (TELO) in Q4 2025, closing a stake of 11,015 shares — an estimated $15.3K sold.

Qube Research & Technologies (QRT) first reported a position in TELO in Q2 2025 and held it in 2 quarters. The position peaked at $33.1K in Q2 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q4 2025.

  • Qube Research & Technologies (QRT) reported no remaining Telomir Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 11,015 Telomir Pharmaceuticals shares in Q4 2025, an estimated $15.3K.
  • Qube Research & Technologies (QRT) first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Qube Research & Technologies (QRT)'s Telomir Pharmaceuticals position peaked at $33.1K in Q2 2025.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q4 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2025, filed 17 Feb 2026.